Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
NCT07583303Phase 1Not yet recruiting
- Sponsor
- City of Hope
- Start
- Dec 2026
- Primary completion
- Apr 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BSB-2002 in acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoints: Incidence of dose-limiting toxicity at 28 days, Frequency and severity of adverse events at 365 days and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
BSB-2002
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07583303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583303.